⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 11, 2024Neurology Neuroimmunology & NeuroinflammationOpen Access

Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis

Leila Husseini Jakob Jung Natalie Boess Niels Kruse Stefan Nessler Christine Stadelmann Imke Metz M. Haupts Martin S. Weber

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess neurofilament light chain serum (sNfL) levels in patients with secondary progressive multiple sclerosis (SP-MS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Husseini et al. (2024) studied this question.

synapsesocial.com/papers/68e609bdb6db64358759cb01 https://doi.org/10.1212/nxi.0000000000200279

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosisCohort Study · 2020 · 163 citations
2Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)Original Research · 2026
3Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials (P6-6.011)2024
4Baseline serum neurofilament light chain: a diagnostic biomarker in drug-naïve multiple sclerosis patients2025 · 1 citations
5Serum neurofilament level as a biomarker in multiple sclerosis2024 · 3 citations